Quick Summary — AZN scores higher on quality with 10.0/10 vs GRFS's 1.7/10. AZN trades at $177.45 while GRFS trades at $7.63. Both analyzed daily using SEC EDGAR data across 13 institutional models.
AZN scores higher with a 10.0/10 quality rating vs GRFS's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $177.45, AZN trades +33.0% above its Bayesian DCF fair value of $118.84, while GRFS at $7.63 trades +71.1% above its estimate of $2.21. GRFS shows a wider gap between price and intrinsic value.
AZN earns a Quality of Company score of 10.0/10 compared to GRFS's 1.7/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
Review the value trap analysis for both AZN and GRFS to assess whether apparent undervaluation reflects genuine opportunity or hidden fundamental risk.
Both AZN and GRFS operate in Drug Manufacturers - General, which has 20 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare AZN vs GRFS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.